VNDA

Vanda Pharmaceuticals Inc. (VNDA) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This summary covers Vanda Pharmaceuticals Inc.'s unaudited financial results for the quarter ended March 31, 2026. Vanda is a global biopharmaceutical company focused on innovative therapies for high unmet medical needs. Its commercial portfolio includes Fanapt (schizophrenia/bipolar I), HETLIOZ (Non-24/SMS), PONVORY (multiple sclerosis), and NEREUS (motion sickness). The company is also advancing BYSANTI (recently approved for bipolar I/schizophrenia) and imsidolimab (generalized pustular psoriasis) through clinical development and regulatory review.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 3% to $51.7 million, driven by a 26% increase in Fanapt sales ($29.6M) and a 10% increase in PONVORY sales ($6.2M). This was partially offset by a 24% decline in HETLIOZ sales ($15.9M) due to generic competition and elevated inventory levels at specialty pharmacies.
• Expense Increases: Selling, general, and administrative (SG&A) expenses surged 36% to $68.4 million, primarily due to expanded commercialization efforts for Fanapt and PONVORY. Research and development (R&D) expenses decreased 20% to $28.4 million, largely due to the absence of a significant upfront payment for the imsidolimab license that occurred in Q1 2025.
• Net Loss Expansion: Net loss widened to $48.6 million from $29.5 million, reflecting higher SG&A costs and a shift from an income tax benefit in the prior year to a small provision in the current quarter.
• Liquidity: Cash and marketable securities decreased by approximately $61.5 million quarter-over-quarter, primarily due to operating cash burn and a $10.0 million milestone payment to Eli Lilly for NEREUS approval.

Guidance, Outlook, and Risks

• Commercial Launches: NEREUS became commercially available in the U.S. on May 1, 2026. BYSANTI was approved by the FDA in February 2026 for bipolar I and schizophrenia, with commercial launch expected soon.
• Regulatory Milestones: The FDA accepted the Biologics License Application (BLA) for imsidolimab with a PDUFA target date of December 12, 2026. Topline results for BYSANTI in major depressive disorder (MDD) and NEREUS for GLP-1 induced vomiting are expected in 2026 or early 2027.
• Liquidity Outlook: Management believes current cash, cash equivalents, and marketable securities ($202.3 million) are sufficient to fund operations for at least the next 12 months, contingent on successful commercialization and regulatory approvals.
• Legal Risks: The company faces ongoing litigation regarding patent infringement for HETLIOZ against generic manufacturers (Teva, Apotex, MSN) and disputes with the FDA regarding approval processes for HETLIOZ (jet lag/insomnia) and NEREUS (gastroparesis). A trial regarding HETLIOZ patents is scheduled for October 2026.
• Valuation Allowance: The company maintains a full valuation allowance against its deferred tax assets, meaning it does not expect to realize these tax benefits in the near term.

Key Investor Verification Points

• HETLIOZ Decline: Verify the sustainability of HETLIOZ revenue given the 24% drop and ongoing generic competition; monitor inventory levels at specialty pharmacies.
• SG&A Trajectory: Assess the impact of the 36% increase in SG&A on future profitability as new products (NEREUS, BYSANTI) launch.
• Legal Outcomes: Monitor the October 2026 trial date for HETLIOZ patent disputes and the status of FDA appeals regarding HETLIOZ and NEREUS indications.
• Cash Burn Rate: Track operating cash flow usage against the $202.3 million liquidity buffer to ensure the 12-month runway remains valid.
• Revenue Disputes: Note that approximately $3.0 million of variable consideration for Fanapt and PONVORY is subject to dispute, which could impact future revenue recognition.